Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

h and Development Expenses40--40Restructuring and Acquisition Integration Charges 22-(22)-Operating Income79-39118Interest Expense and Other, Net 23--23Income Before Income Tax56-3995Provision for Income Taxes20-1131Income from Continuing Operations36-2864Income from Discontinued Operations, Net of Tax2(2)---Net Income

$

38

$

(2)

$

28

$

64.Per Share Amounts:(4)Basic Earnings per Common Share

$

0.17

$

(0.01)

$

0.13

$

0.29Diluted Earnings per Common Share

$

0.17

$

(0.01)

$

0.13

$

0.29Weighted-Average Number of Common Shares Outstanding:Basic222.1222.1222.1222.1Diluted223.9223.9223.9223.9Effective Tax Rate34.4%n/a27.8%31.7%____________1Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations. 2Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. CAREFUSION CORPORATIONADJUSTED SEGMENT FINANCIAL INFORMATION(UNAUDITED)Quarter Ended September 30, 2011Nonrecurring(in millions)GAAP Items(1)Adjusted(3)Medical SystemsRevenue$

509

$

-

$

509Operating Income $

88

$

7

$

95Procedural SolutionsRevenue$

335

$

-

$

335Operating Income $

20

$

4

$

24Quarter Ended September 30, 2010No
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
(Date:4/30/2015)... April 30, 2015  The Paul G. Allen Family ... (ADI) grants to six groups of researchers with projects ... roadblocks in neuroscience: growing mature human brain cells in ... of $7.5 million over three years.  ... research is especially significant because the field of neuronal ...
(Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: ... ) today announced that the U.S. Food and Drug Administration ... BYETTA is now approved for use as a stand-alone medication ... in adults with type 2 diabetes. Previously, it was approved ...
... Calif., Oct. 30 ThermoGenesis Corp. (Nasdaq: ... and store adult stem cells, announced today it will report ... 2009, on Thursday, November 5, 2009. , ... host a conference call Thursday, November 5, 2009 at 2:00 ...
... , ROCKVILLE, Md., Oct 30 Novavax, Inc. (Nasdaq: ... third quarter financial results in a press release to be ... 2009. The Company will hold an investor conference call to ... Friday, November 6, 2009. The call will be hosted by ...
Cached Biology Technology:BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call 2
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The first real-world, demonstration-scale project in Nevada for ... stage of research at the University of Nevada, Reno. ... is an economical, commercially viable renewable energy source in ... outdoor cold-weather crop of algae as part of their ...
... TGen Clinical Research Services (TCRS) at Scottsdale Healthcare ... may offer broad potential to treat solid tumors. ... conducted at TGen Clinical Research Services at Scottsdale Healthcare, ... (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo ...
... bleaching is not only a con, but is dangerous to ... journal. The light treatment gives absolutely no benefit over ... four times as much as sunbathing, reports a study in ... match Tom Cruise,s glittering pearly-whites would be better off ignoring ...
Cached Biology News:Success for first outdoor, large-scale algae-to-biofuel research project in Nevada 2TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: